Market research
HLVX Hillevax Inc
NASDAQ USD Healthcare
Latest close
As of 17 Oct 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 105M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 0.77
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 105M
- P/E ratio
- Not available
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 0.77
About
About Hillevax Inc
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. As of September 17, 2025, HilleVax, Inc. operates as a subsidiary of XOMA Royalty Corporation.
Research context
Hillevax Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the HLVX discussion.
No comments yet
Start a focused discussion about HLVX.